EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

The Australia story: Current status and future challenges for the clinical applications of psychedelics

David J Nutt, Peter Hunt, Anne Katrin Schlag iD, Paul Fitzgerald

British Journal of Pharmacology · 2026

DOI: 10.1111/bph.17398 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, 2026. Written by David J Nutt and 3 co-authors. Institution: Imperial College London and Drug Science, London, UK. Major MEDLINE topics: Hallucinogens, N-Methyl-3,4-methylenedioxyamphetamine, Psilocybin. Cited 22 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic Goods Administration (TGA) approved the use of psilocybin for treatment‐resistant depression and MDMA for PTSD to take effect from 1 July 2023. The campaign for TGA approval was led by a coalition comprising the Australian charity Mind Medicine Australia with support from Professor David Nutt, Drug Science, Professor Arthur Christopolous, Professor Chris Langmead (both from Monash University) and from large numbers of clinical, academic and patient groups. Under the rescheduling, current prescribing rights are limited to psychiatrists who have become authorised prescribers under the TGA's Authorised Prescriber Scheme, and psilocybin can only be used for treatment resistant depression and MDMA can only be used for PTSD. This paper reviews the background for this decision, its implications for approvals in other jurisdictions, as well as for the development pathways for other psychedelic drugs. LINKED ARTICLES This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc

Subjects

MeSH terms (MEDLINE)

HallucinogensN-Methyl-3,4-methylenedioxyamphetaminePsilocybinHumansAustraliaAnimalsDrug ApprovalDepressive Disorder, Treatment-Resistant

Author keywords

3,4‐methylenedioxymethamphetamine (MDMA)Australiapsilocybinpsychedelicstherapeutic goods administration (TGA)

Substances

HallucinogensN-Methyl-3,4-methylenedioxyamphetaminePsilocybin

Authors and institutions

  • Imperial College London and Drug Science, London, UK.
  • Mind Medicine Australia, Melbourne, Victoria, Australia.
  • Drug Science and Imperial College London, London, UK.
  • School of Medicine and Psychology, Australian National University, Canberra, ACT, Australia.

ORCID profiles: Anne Katrin Schlag

Cite

APA

Nutt, D. J., Hunt, P., Schlag, A. K., & Fitzgerald, P. (2026). The Australia story: Current status and future challenges for the clinical applications of psychedelics. British Journal of Pharmacology. https://doi.org/10.1111/bph.17398

Vancouver

Nutt DJ, Hunt P, Schlag AK, Fitzgerald P. The Australia story: Current status and future challenges for the clinical applications of psychedelics. British Journal of Pharmacology. 2026. doi:10.1111/bph.17398

BibTeX
@article{Nutt2026,
  author = {Nutt, David J and Hunt, Peter and Schlag, Anne Katrin and Fitzgerald, Paul},
  title = {The Australia story: Current status and future challenges for the clinical applications of psychedelics},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.17398}
}
Start for free →